CNTA CENTESSA PHARMACEUTICALS PLC

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Guggenheim Emerging Outlook: Biotech Summit

Date: Thursday, February 12, 2026

Fireside Chat: 1:00 PM ET

Event: TD Cowen 46th Annual Health Care Conference

Date: Tuesday, March 3, 2026

Fireside Chat: 3:10 PM ET

Event: Leerink Partners Global Healthcare Conference

Date: Tuesday, March 10, 2026

Fireside Chat: 8:00 AM ET

Event: Jefferies Biotech on the Beach Summit

Date: Wednesday, March 11, 2026

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at /events-presentations.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit , which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations



EN
03/02/2026

Underlying

CNTACENTESSA PHARMACEUTICALS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTESSA PHARMACEUTICALS PLC

 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Emerging Outlook: Biotech SummitDate: Thursday, February 12, 2026Fireside Chat: 1:00 PM ET Event: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat: 3:10 PM ET Event: Leerin...

20h / 46m 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Poster Presentation of New Preclini...

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder BOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, today announced the presentation of new preclinical da...

January 14, 2026 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces CEO Transition as Company Advances ...

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications  Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, as Chief Executive O...

December 11, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offe...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and comm...

November 12, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Proposed Public Offering of America...

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offeri...

November 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch